Concept:
Neonatal lupus erythematosus (NLE) is an acquired autoimmune disorder caused by the transplacental transfer of maternal anti-SSA/Ro and/or anti-SSB/La autoantibodies.
The most severe complication is congenital heart block (CHB), which carries high fetal and neonatal morbidity, necessitating strict antenatal monitoring and safe pharmacotherapy while strictly avoiding teratogens.
Explanation:
• Congenital complete heart block develops predominantly between 16 and 28 weeks of gestation due to antibody-mediated autoimmune injury and subsequent fibrosis of the fetal atrioventricular (AV) node.
• Hydroxychloroquine (HCQ) is strongly recommended during pregnancy in anti-Ro/SSA-positive mothers because it significantly reduces the recurrence and incidence of fetal cardiac lupus by downregulating TLR signaling.
• Fluorinated corticosteroids such as dexamethasone or betamethasone cross the placenta without being inactivated by $11\beta$-hydroxysteroid dehydrogenase type 2 and are utilized to treat emerging incomplete heart block (first- or second-degree) or associated fetal myocarditis.
• Beta-sympathomimetic agents such as terbutaline are often combined with dexamethasone when significant fetal bradycardia (heart rate $<55\text{ bpm}$) is present to improve fetal cardiac output.
• Leflunomide is an inhibitor of pyrimidine synthesis that is categorized as Category X (strictly contraindicated in pregnancy) due to potent embryotoxic and teratogenic effects; it must never be used antenatally.
Final Answer:
Leflunomide is strictly contraindicated and not recommended antenatally because of its severe teratogenicity and lack of efficacy for fetal cardiac lupus.